Clinical Research Directory

Inclusion Criteria: 1. Aged 18 years and above, regardless of gender; 2. Meet the DSM-5 diagnostic criteria for mental disorders (any type); 3. Insomnia Severity Index (ISI) score ≥11; 4. Have at least 7 hours of sleep time available; 5. Able to complete the 2-month scale assessment and follow-up plan; 6. Voluntarily sign the informed consent form; 7. Intend to receive lemborexant treatment as judged by the clinicians Exclusion Criteria: 1. Mental disorder is in the acute phase as judged by clinical assessment, or the dose of other psychotropic drugs cannot be stabilized during the study; 2. Concurrent use of ≥2 types of benzodiazepine receptor agonists (BZRAs) as insomnia treatment drugs; 3. Previous continuous use of dual orexin receptor antagonist (DORA)-type drugs for \>1 week; 4. Clear suicide attempt/plan or high suicide risk as judged by the researcher; 5. Pregnant or lactating women; 6. Patients with narcolepsy; 7. Patients with severe hepatic insufficiency; 8. Currently accompanied by severe or unstable diseases of cardiovascular, respiratory, digestive and other systems; 9. Other conditions deemed unsuitable for participation by the researcher